Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.

Nature reviews. Clinical oncology·2026
Same author

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study.

HemaSphere·2026
Same author

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology·2026
Same author

Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.

Blood advances·2026

Related Experiment Video

Updated: Mar 24, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K

Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management.

Wan Danial Noor1,2, John F Seymour3,4, Chan Yoon Cheah1,2,5

  • 1Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.

American Journal of Hematology
|March 23, 2026
PubMed
Summary

Marginal zone lymphoma (MZL) is a diverse B-cell cancer with three main subtypes. Advances in genomic testing, classification systems, and prognostication tools aid diagnosis and treatment strategies for MZL.

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

991
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Related Experiment Videos

Last Updated: Mar 24, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

991
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Marginal zone lymphoma (MZL) encompasses heterogeneous indolent mature B-cell neoplasms.
  • Classically, three subtypes exist: nodal, splenic, and extranodal MZL of mucosa-associated lymphoid tissue (MALT).

Purpose of the Study:

  • To provide an overview of Marginal Zone Lymphoma (MZL) diagnosis and treatment.
  • To highlight recent advancements in classification, prognostication, and therapeutic approaches for MZL.

Main Methods:

  • Genomic testing and PET/CT scans are crucial for diagnosis and staging.
  • The RECLASS system and FIL-NF10 classification introduced new approaches and a fourth subtype (disseminated MZL).
  • Prognostic indices like MZL IPI and FLIPI24 aid in predicting outcomes.

Main Results:

  • Frontline treatment differs for localized versus advanced MZL.
  • Localized disease may be treated with radiotherapy, antimicrobials, or rituximab.
  • Advanced disease management involves systemic immunotherapy/chemotherapy, with emerging roles for covalent Bruton tyrosine kinase inhibitors (cBTKi).

Conclusions:

  • cBTKi and immunomodulators are established for relapsed/refractory MZL.
  • Ongoing research explores antibody-drug conjugates, T-cell engagers, and CAR T-cell therapies.
  • Personalized treatment strategies are evolving based on subtype, stage, and emerging therapies.